Marketed in 46 countries across Europe, the Americas, and parts of Asia, Vigamox is a globally distributed brand of moxifloxacin, classified within the bactericidal and ophthalmological categories. The breadth of its registration means travellers and expatriates regularly encounter the brand in pharmacies far from where it was first prescribed, which is the situation this page is written for.
The active ingredient, moxifloxacin, is used in the management of bacterial infections, with indications that span ophthalmic infections such as bacterial conjunctivitis as well as certain respiratory and other systemic bacterial infections. The structured indication block further down this page lists each registered use as recognised by national regulators in the markets where Vigamox is sold.
Because Vigamox carries marketing authorisation across a wide regulatory spread — including Germany, Canada, Chile, Finland, and Hong Kong among others — the same active ingredient is sometimes encountered under the Vigamox brand and sometimes as a moxifloxacin-containing product sold under another name. Packaging, prescription pathways, and even the form in which moxifloxacin is supplied can differ noticeably from one country to another, and a local pharmacist is generally the most efficient point of contact for confirming whether a moxifloxacin product on a regional shelf corresponds to what was originally prescribed.
Other antibacterial agents within the broader bactericidal class also circulate internationally under their own molecules and brand names, but they are not interchangeable with moxifloxacin without medical input — antibacterial choice depends on the specific infection, local resistance patterns, and patient history. Anyone already taking Vigamox, considering it, or trying to identify a regional equivalent should treat the question as a clinical one and bring it to a healthcare provider rather than resolving it at the counter.
No information provided.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The most frequently reported ocular adverse events were conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, and tearing. These events occurred in approximately 1-6% of patients.
Nonocular adverse events reported at a rate of 1-4% were fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.
Plasma concentrations of moxifloxacin were measured in healthy adult male and female subjects who received bilateral topical ocular doses of VIGAMOX® solution 3 times a day. The mean steady-state Cmax (2.7 ng/mL) and estimated daily exposure AUC (45 ng•hr/mL) values were 1,600 and 1,000 times lower than the mean Cmax and AUC reported after therapeutic 400 mg doses of moxifloxacin. The plasma half-life of moxifloxacin was estimated to be 13 hours.
Pregnancy Category C.
Teratogenic EffectsMoxifloxacin was not teratogenic when administered to pregnant rats during organogenesis at oral doses as high as 500 mg/kg/day (approximately 21,700 times the highest recommended total daily human ophthalmic dose); however, decreased fetal body weights and slightly delayed fetal skeletal development were observed. There was no evidence of teratogenicity when pregnant Cynomolgus monkeys were given oral doses as high as 100 mg/kg/day (approximately 4,300 times the highest recommended total daily human ophthalmic dose). An increased incidence of smaller fetuses was observed at 100 mg/kg/day.
Since there are no adequate and well-controlled studies in pregnant women, VIGAMOX® solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Vigamox is used in the management of bacterial infections, with registered indications that include bacterial conjunctivitis and other ophthalmic infections, as well as certain respiratory and systemic bacterial conditions. The active ingredient is bactericidal, meaning it acts directly on susceptible bacteria. The structured indication list on this page details each registered use as recognised by national regulators in the markets where Vigamox is sold.
Vigamox contains moxifloxacin, classified within the bactericidal and ophthalmological categories. Moxifloxacin is the same molecule whether sold under the Vigamox brand or as a generic, and the active ingredient circulates internationally under several different commercial names depending on the manufacturer and the regulatory market in which the product is registered.
Vigamox is registered in 46 countries spanning Europe, the Americas, and parts of Asia. Representative markets include Canada, Germany, Argentina, Hong Kong, Finland, Chile, and the Czech Republic. If your country is not represented in the list shown on this page, a local pharmacist can usually confirm whether moxifloxacin is available in that market under a different brand name or as a generic equivalent.
Moxifloxacin is sold under several brand names worldwide, particularly in markets where the original patent has expired and multiple manufacturers produce moxifloxacin-containing products in parallel. Other antibacterial agents within the broader bactericidal class also exist, although they are not interchangeable without medical guidance. To identify a local moxifloxacin product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Vigamox is a prescription medication in most regulatory markets, and antibacterial therapy in general is calibrated to the specific infection, local resistance patterns, and the patient's broader clinical picture. This matters particularly for travellers and people relocating between countries, since prescription rules, available formulations, and brand names differ across regimes. Any decision to start, stop, or substitute moxifloxacin should involve a healthcare provider.
